Enanta Pharmaceuticals | ENTA - Capital Ordinário





Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Amgen USD 541M 1000K 2026-06
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Insmed USD 218.28M 1.76M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.64M 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 4.93M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
Vertex Pharmaceuticals USD 253.3M 900K 2026-06